Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC.CYPH · Entity 6392 | Director | March 13, 2026 | March 17, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYPHERPUNK TECHNOLOGIES INC.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,750 |
Ending reported balance
After 2026-03-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-13 · Exercise / conversion · Acquired 74,700 · Balance 74,700 F1: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). Row 2 · 2026-03-13 · Exercise / conversion · Acquired 94,050 · Balance 168,750 F2: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-13 · Exercise / conversion · Disposed 74,700 · Balance 0 F1: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). F3: The November 2025 RSUs vested at issuance on their grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-13 · Exercise / conversion · Disposed 94,050 · Balance 0 F2: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. F4: The December 2025 RSUs vested at issuance on their grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock").
F2: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock.
F3: The November 2025 RSUs vested at issuance on their grant date.
F4: The December 2025 RSUs vested at issuance on their grant date.
IONIS PHARMACEUTICALS INC
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30 | Direct | 5,369 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,521 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 2,301 · Balance 7,521 F3: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 22:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 2,301 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000231 · edgardoc.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,521 Underlying: Common Stock · 2,301 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026. F4 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,369 | $0.00 Strike: $79.19 | $0.00 |
DisclosureSEC source: 0000874015-26-000231 · edgardoc.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2036-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. F2 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $64.80 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 14 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2029-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $60.20 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 13 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 12 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,321 | $0.00 Strike: $41.08 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 11 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,321 shares Expires 2033-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 10 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2031-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,968 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · derivative · entry 9 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,968 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 17,781 | $75.58 | $1,343,934.21 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 8 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.495 to $75.98 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 59,508 | $74.90 | $4,457,292.02 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 7 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,111 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.49 to $75.49 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,000 | $64.80 | $1,036,800.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 6 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,000 | $60.20 | $722,400.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 5 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,000 | $42.88 | $686,080.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,321 | $41.08 | $423,986.68 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,000 | $40.05 | $480,600.00 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:27 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,968 | $38.06 | $417,442.08 |
DisclosureSEC source: 0000874015-26-000183 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 94,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029634 · tm269084-2_4seq1.xml · derivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. F4 · derivative.exercise_date: The December 2025 RSUs vested at issuance on their grant date. F4 · derivative.expiration_date: The December 2025 RSUs vested at issuance on their grant date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 74,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029634 · tm269084-2_4seq1.xml · derivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). F3 · derivative.exercise_date: The November 2025 RSUs vested at issuance on their grant date. F3 · derivative.expiration_date: The November 2025 RSUs vested at issuance on their grant date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 94,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-029634 · tm269084-2_4seq1.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. F2 · price: 94,050 RSUs previously granted by the Company to the reporting person on December 23, 2025 pursuant to the Company's 2025 Equity Incentive Plan for no consideration (the "December 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of Common Stock. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | Exercise / conversionCommon Stock | 74,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-029634 · tm269084-2_4seq1.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). F1 · price: 74,700 Restricted Stock Units ("RSUs") previously granted by Cypherpunk Technologies Inc. (the "Company") to the reporting person on November 11, 2025 pursuant to the Company's 2022 Equity Incentive Plan for no consideration (the "November 2025 RSUs") were settled on March 13, 2026 on a 1 for 1 basis for shares of the Company's common stock, par value $0.001 per share ("Common Stock"). Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 200 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · derivative · entry 6 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,968 Underlying: Common Stock · 200 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 200 | $80.00 | $16,000.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 200 | $38.06 | $7,612.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 832 | $0.00 Strike: $38.06 | $0.00 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · derivative · entry 5 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,168 Underlying: Common Stock · 832 shares Expires 2032-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 832 | $80.33 | $66,832.81 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.035 to $81.01 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 23:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 832 | $38.06 | $31,665.92 |
DisclosureSEC source: 0000874015-26-000138 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:36 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 94,050 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-125260 · tm2534450-7_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,050 Underlying: Common Stock · 94,050 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2025 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F2 · derivative.expiration_date: The RSUs vested at issuance on December 23, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:56 UTC | CYPHERPUNK TECHNOLOGIES INC. CYPH · Entity 6392 | GrantRestricted Stock Units · Derivative | 74,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-111440 · tm2531210-6_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,700 Underlying: Common Stock · 74,700 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") to be settled on a 1 for 1 basis for shares of Cypherpunk Technologies Inc. ("Company") common stock, par value $0.001 per share ("Common Stock"). The RSUs were awarded pursuant to the Company's 2022 Equity Incentive Plan for no consideration. F2 · derivative.exercise_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. F2 · derivative.expiration_date: The RSUs vested at issuance on November 11, 2025 (the "Grant Date"). Subject to the terms of the RSU award and applicable tax withholdings, the Company shall settle the RSUs for Common Stock as soon as practicable following the earlier to occur of (i) the fifth (5th) business day after the date the reporting person ceases for any reason to be a member of the Company's Board of Directors or (ii) the date of the first annual meeting of stockholders of the Company that occurs following the Grant Date. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0000874015-25-000271 · edgardoc.xml · derivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 16,000 | $75.10 | $1,201,668.80 |
DisclosureSEC source: 0000874015-25-000271 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.47 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,000 | $52.22 | $835,520.00 |
DisclosureSEC source: 0000874015-25-000271 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-25-000212 · edgardoc.xml · derivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 16,000 | $60.15 | $962,371.20 |
DisclosureSEC source: 0000874015-25-000212 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,330 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.57 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 16,000 | $24.42 | $390,720.00 |
DisclosureSEC source: 0000874015-25-000212 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:59 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 4,079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000162 · edgardoc.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,220 Underlying: Common Stock · 4,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:59 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,079 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000162 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 5,220 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000141 · edgardoc.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,299 Underlying: Common Stock · 5,220 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:53 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,518 | $0.00 Strike: $39.94 | $0.00 |
DisclosureSEC source: 0000874015-25-000141 · edgardoc.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518 Underlying: Common Stock · 11,518 shares Expires 2035-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 22:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 13,508 | $37.86 | $511,426.39 |
DisclosureSEC source: 0000874015-24-000239 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,251 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.62 to $38.595 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:25 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-106338 · tm2425653-6_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of December 31, 2024, March 31, 2025, June 30, 2025, and September 30, 2025 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 4,677 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000181 · edgardoc.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,079 Underlying: Common Stock · 4,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 21:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,677 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000181 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 4,079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-24-000164 · edgardoc.xml · derivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,756 Underlying: Common Stock · 4,079 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. F4 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,111 | $0.00 Strike: $47.11 | $0.00 |
DisclosureSEC source: 0000874015-24-000164 · edgardoc.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:33 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-24-009021 · tm244775-11_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-29 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:30 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001104659-23-095359 · tm2324823-5_4seq1.xml · derivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-08-23 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 4 quarterly installments on each of November 23, 2023, February 23, 2024, May 23, 2024 and August 23, 2024 for so long as the reporting person continues to be a director, consultant or service provider of the Company. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:06 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000177 · edgardoc.xml · derivative · entry 4 LOSCALZO JOSEPH · CIK 0001276128 · Director · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,677 Underlying: Common Stock · 5,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:06 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 1,777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000177 · edgardoc.xml · derivative · entry 3 LOSCALZO JOSEPH · CIK 0001276128 · Director · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,010 Underlying: Common Stock · 1,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:06 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000177 · edgardoc.xml · nonDerivative · entry 2 LOSCALZO JOSEPH · CIK 0001276128 · Director · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:06 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,777 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-23-000177 · edgardoc.xml · nonDerivative · entry 1 LOSCALZO JOSEPH · CIK 0001276128 · Director · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.